Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN ...

Researchers at the Centre for Genomic Regulation and the Wellcome Sanger Institute have comprehensively identified the allosteric control sites found in the protein KRAS, which is one of the most ...

A presentation given by Mikhail Kalinichev, Head of Translational Science at Addex will describe the progress seen to date with the Addex GABAB PAM cough program, including antitussive data from in ...

Allosteric sites are often preferred for drug development as they offer greater specificity, reducing the likelihood of side effects. They can also change a protein's activity more subtly ...

The full invitation to the AGM 2025 may be found in the General Meetings section of the Company's website here.

Neurosterix has stepped out of the shadows with $63 million from a first-round financing led by life sciences investment group Perceptive Advisors that will be used for a portfolio of allosteric ...

This new article publication from Acta Pharmaceutica Sinica B, discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain ...

EAI-432, an allosteric inhibitor with high selectivity for the L858R mutation and subsequent clinical resistance mutations, provides a potential new approach for NSCLC patients for whom there are ...

ETX-636 is a novel orally bioavailable allosteric pan-mutant-selective PI3Kα inhibitor and degrader. This dual mechanism of action results in deep and durable pathway inhibition and induces ...

Ad Hoc Announcement Pursuant to Art.?53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...